Latest News & Updates

FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer
February 6, 2023

Continue Reading »

FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma
December 23, 2022

Continue Reading »

FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer
December 19, 2022

Continue Reading »

FDA approves sacituzumab govitecan-hziy for HR-positive breast cancer
February 6, 2023

Continue Reading »

FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma
December 23, 2022

Continue Reading »

FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer
December 19, 2022

Continue Reading »

FDA approves updated drug labeling including new indications and dosing regimens for capecitabine tablets under Project Renewal
December 15, 2022

Continue Reading »

Get More from FLASCO With Your Membership

The Corporate Membership Program allows FLASCO to expand our offerings to our membership. Every FLASCO meeting also provides the industry representative with opportunities to educate our members. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Members:

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: